Synthetic insulin
2. Zammitt N. and Frier, B, (2005) ‘ Hypoglycemia in Type 2 Diabetes ’, Diabetes Care 28(12): 2948- 2961 3. Best, C. and Scott, D. (1923) ‘ The Preparation of Insulin ’, Journal of Biological Chemistry 57: 709- 723 4. Sanger, F. (1958) ‘ The Chemistry of Insulin: Nobel Lecture ’ , December 11, 1958. Nobel Lectures, Chemistry 1942-1962 . Elsevier Publishing Company. Amsterdam. 1964 5. Thorens, B. (2011) ‘ Brain glucose sensing and neural regulation of insulin and glucagon secretion ’, Diabetes, Obesity and Metabolism 13 (Suppl. 1): 82 – 88 6. Green, N/, Stout, G., Taylor, D. and Soper, R. (1990) Biological Science 2: Systems, Maintenance and Change. Second edition . Cambridge 7. Kumar, P. and Clark, M. (1994) Clinical Medicine, Third Edition (revised) . London. 8. Shah, B. and Zinman, B. (2002) The treatment of type 1 diabetes mellitus , in Wass, J. and Shalet, S. (eds): Oxford Textbook of Endocrinology and Diabetes. Oxford. 9. Bliss, M. (1982) The Discovery of Insulin. Toronto. 10. Steiner, D. (2011) ‘ Adventures with Insulin in the Islets of Langerhans ’, The Journal of Biological Chemistry 286(20): 17399-17421 11. Heise, T. and Mathieu, C. (2017) ‘ Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes ’. Diabetes, Obesity and Metabolism 19(1): 3-12 12. Brow, A., Steel, J., Duncan, C., Duncan, A. and McBain, A. (2004). ‘ An assessment of the adequacy of suspension of insulin in pen injectors ’, Diabetic Medicine 21: 604-608 13. European Medicines Agency (2005) Lantus European Public Assessment Report Scientific Discussion . At https://www.ema.europa.eu/en/documents/scientific-discussion/lantus-epar-scientific- discussion_en.pdf (accessed 22 August 2019) 14. Website: https://www.bbc.co.uk/bitesize/guides/zx6g87h/revision/2 (accessed 22 August 2019). 15. European Medicines Agency (2004). Levemir European Public Assessment Report Scientific Discussion . At https://www.ema.europa.eu/en/documents/scientific-discussion/levemir- epar-scientific-discussion_en.pdf (accessed 22 August 2019) 16. Heise, T., Nosek, L., Biilmann Rønn , B., Endahl, L., Heinemann, L/, Kapitza, C. and Draeger, E. (2004). ‘ Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes ’, Diabetes 53: 1614-1620 17. Heise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S. and Haahr, H. (2017). ‘ Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/ml in type 1 diabetes ’ , Diabetes, Obesity and Metabolism 19(7):1032- 1039 18. European Medicines Agency (2013). Tresiba European Summary of Product Characteristics . At https://www.ema.europa.eu/en/documents/product-information/tresiba-epar-product- information_en.pdf (accessed 22 August 2019) 19. Zaykov, A., Mayer, J. and DiMarchi, R. (2016). ‘ Pursuit of a perfect insulin ’ Nature Reviews Drug Discovery 15: 425-439
200
Made with FlippingBook - Online catalogs